AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18520295
Drug: Vandetinib administered
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vandetinib administered concurrently with chemotherapy
Trial: 15808378
Drug: Vaginal insert
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal insert (10 mg over 12 h)
Trial: 15808378
Drug: Cervical gel
RxNorm normalized name: ENDOCERVICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical gel (0.5 mg, twice in 12 h)
Trial: 10522767
Drug: Nursing intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nursing intervention using Orem's self‐care theory, five 30‐min sessions once a week during treatment and two follow-up sessions after treatment.
Trial: 8527016
Drug: Paediatric ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Paediatric ibuprofen
Trial: 7017017
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of doxycycline per dose, taken biweekly for three weeks
Trial: 7017017
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of doxycycline per dose
Trial: 27852695
Drug: Methotrexate +
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate + Infliximab (M+I) (5 mg/kg)
Trial: 27852695
Drug: Infliximab therapy
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab therapy (after 54 weeks)
Trial: 26399192
Drug: Constraint-Induced Aphasia
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-Induced Aphasia Therapy (CIAT), 4 hours/day for 10 consecutive business days (total 40 hours)
Trial: 23422107
Drug: rhPTH (1-34)
RxNorm normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhPTH (1-34) 20 µg daily for 18 months
Trial: 23422107
Drug: elcatonin 20
RxNorm normalized name: melatonin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elcatonin 20 U weekly for 12 months
Trial: 14749206
Drug: Rosiglitazone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (8 mg/day for 24 weeks)
Trial: 8091041
Drug: Alternative treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative treatments for rheumatoid arthritis
Trial: 21355716
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) Regular Human Insulin (RHI)
Trial: 21355716
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) Insulin Lispro (IL)
Trial: 21355716
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) Insulin Lispro (IL) and Regular Human Insulin (RHI)
Trial: 20690287
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of teacher instruction and peer education (E3)
Trial: 510179
Drug: Ethanol, 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol, 0.8 ml/kg
Trial: 25735992
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg JNJ-40411813
Trial: 25735992
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg JNJ-40411813
Trial: 25735992
Drug: 150-225 mg
RxNorm normalized name: aminophylline 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150-225 mg JNJ-40411813
Trial: 25735992
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg JNJ-40411813
Trial: 22290001
Drug: 200 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 µg NTG plus 3 mg/kg 2% lidocaine
Trial: 22290001
Drug: 300 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 µg NTG plus 3 mg/kg 2% lidocaine
Trial: 22290001
Drug: 400 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 µg NTG plus 3 mg/kg 2% lidocaine
Trial: 22290001
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg 2% lidocaine diluted with saline (Control Group LS)
Trial: 19653788
Drug: Medication Contingencies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Contingencies (MC)
Trial: 16409324
Drug: Aqueous 17%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous 17% (w/v) ethylenediaminetetraacetic acid rinse for 2 or 10 min followed by a 2% Patent Blue dye solution for 2 or 10 min
Trial: 16409324
Drug: Tap water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tap water rinse for 2 or 10 min followed by a 2% Patent Blue dye solution for 2 or 10 min
Trial: 11423841
Drug: Topical 20%
RxNorm normalized name: urea topical 20% topical foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 20% aminolevulinic acid hydrochloride (ALA) with optimal light dose of 10 J/cm²
Trial: 11423841
Drug: Vehicle treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle treatment with light
Trial: 3318751
Drug: Corticosteroid tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corticosteroid tapering regimen of one week
Trial: 3318751
Drug: Corticosteroid tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corticosteroid tapering regimen of seven weeks
Trial: 22577172
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg rhTSH (n = 42)
Trial: 20979754
Drug: Esmolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (1 mg/kg intravenously followed by 150 microg x kg(‐1) x min(‐1) intravenous infusion)
Trial: 15465443
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of l-dopa
Trial: 11833926
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi intervention (6-month, twice a week)
Trial: 7979119
Drug: 5% EMLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% EMLA cream (lidocaine and prilocaine), applied to the venepuncture site for at least 60 minutes.
Trial: 7979119
Drug: Placebo cream,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream, applied to the venepuncture site for at least 60 minutes.
Trial: 864062
Drug: no treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no treatment controls
Trial: 864062
Drug: alternative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alternative treatment conditions
Trial: 21569574
Drug: Neoadjuvant ADT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant ADT for ≥10 months after PSA reached < 0.2 ng/ml
Trial: 21569574
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of neoadjuvant ADT from when PSA reached < 0.2 ng/ml to surgery
Trial: 17140281
Drug: Oral ziprasidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ziprasidone 40-80 mg twice daily for acute illness
Trial: 17140281
Drug: Oral ziprasidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ziprasidone 20-80 mg twice daily for chronic schizophrenia or schizoaffective disorder
Trial: 17140281
Drug: Intramuscular ziprasidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ziprasidone for acute agitation
Trial: 9402180
Drug: GEM 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEM 1,200 mg/m2 + VNR 25 mg/m2
Trial: 9402180
Drug: GEM 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEM 1,200 mg/m2 + VNR 20 mg/m2
Trial: 9402180
Drug: GEM 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEM 1,000 mg/m2 + VNR 25 mg/m2
Trial: 8218536
Drug: Initial induction
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial induction consolidation chemotherapy for newly diagnosed AML
Trial: 2438841
Drug: Blue-green argon
RxNorm normalized name: BLUE GREEN ALGAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue-green argon laser treatment
Trial: 2438841
Drug: Red krypton
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red krypton laser treatment
Trial: 14511962
Drug: Oral plus
RxNorm normalized name: Acetaminophen/Dexbrompheniramine Maleate/Pseudoephedrine Hydrochloride 500 MG-3 MG-60 MG Oral Tablet, Extended Release [DRIXORAL PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral plus continued oral misoprostol (0.4 mg twice daily for 7 days)
Trial: 14511962
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol plus continued oral misoprostol (0.4 mg twice daily for 7 days)
Trial: 10389710
Drug: Negative fetal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative fetal fibronectin test with 0.5 mg PGE2 gel
Trial: 8896855
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g EMLA cream
Trial: 1670586
Drug: Interleukin-2 (IL-2)
RxNorm normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 (IL-2) plus zidovudine (ZDV), daily doses of IL-2 from 1.5 to 12 x 10(6) IU/m2
Trial: 1670586
Drug: Interleukin-2 (IL-2)
RxNorm normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 (IL-2) plus zidovudine (ZDV), higher doses of IL-2
Trial: 4072925
Drug: Chlorthalidone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (25 to 50 mg/day)
Trial: 30306399
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of undirected movement and cognitive load
Trial: 20188847
Drug: Systemic theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic theophylline (nonselective adenosine receptor antagonist)
Trial: 20188847
Drug: Inhaled lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled lidocaine (local anesthetic)
Trial: 15502060
Drug: Patient-controlled epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled epidural analgesia (PCEA) with 0.08% bupivacaine and fentanyl 1.6 microg/mL
Trial: 8349066
Drug: Oral omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral omeprazole, 40 mg per day (n = 31)
Trial: 8349066
Drug: Injection therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection therapy (adrenaline 1:10,000 plus polidocanol 1% injection associated with oral ranitidine 300 mg per day) (n = 21)
Trial: 28419997
Drug: Genetically predicted
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically predicted soluble plasma leptin receptor (sOB-R) levels
Trial: 26332539
Drug: USL261 (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USL261 (2.5, 5.0, and 7.5 mg)
Trial: 26332539
Drug: MDZ-inj IN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDZ-inj IN (5.0 mg)
Trial: 26332539
Drug: MDZ-inj IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDZ-inj IV (2.5 mg)
Trial: 24172626
Drug: Systemic peroral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic peroral antibiotics
Trial: 21444869
Drug: 24-hour infusion
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour infusion of high-dose methotrexate (HDMTX; 1 g/m(2))
Trial: 21444869
Drug: 4-hour infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-hour infusion of high-dose methotrexate (HDMTX; 1 g/m(2))
Trial: 16865997
Drug: Oral‐B Sonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral‐B Sonic Complete
Trial: 16865997
Drug: Oral‐B Indicator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral‐B Indicator (manual)
Trial: 12953289
Drug: Immunoglobulin (IgG)
RxNorm normalized name: immunoglobulin A
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin (IgG) enzyme‐linked immunosorbent assay (ELISA) for measuring serum antibody concentrations
Trial: 11062357
Drug: Alendronate (ALN;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (ALN; 10 mg/day) for 2 years
Trial: 11062357
Drug: Alendronate (ALN;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (ALN; 10 mg/day) for 3 years
Trial: 9425591
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with a mixture of multiple allergen extracts
Trial: 9425591
Drug: Injection therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection therapy using synthetic fragments of the major allergen responsible for allergic reactions to cats
Trial: 8375429
Drug: Bromocriptine-levodopa combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine-levodopa combination therapy
Trial: 3758170
Drug: Naloxone (0.4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.4, 1.2, 3.6, 10.8, 32.4, 97.2 mg)
Trial: 30721950
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized P4 (3 × 200 mg/d IM)
Trial: 30721950
Drug: E2 (5
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E2 (5 mg IM) and oral placebo
Trial: 30721950
Drug: E2 IM
RxNorm normalized name: Estradiol Intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 IM and oral micronized P4
Trial: 21177179
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy plus sulfasalazine delivered via a colon therapy system
Trial: 21177179
Drug: Sulfasalazine delivered
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfasalazine delivered via colon therapy system
Trial: 9725371
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of local anesthetics (bupivacaine) and opioid analgesics (fentanyl) through a thoracic epidural catheter
Trial: 16509426
Drug: Pharmacotherapy by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy by fluvoxamine
Trial: 16509426
Drug: Controlled therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled therapy
Trial: 10767520
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate plus L-thyroxine (75 mcg/day for 3 months)
Trial: 10767520
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (100 mg/day for 5 days/month for 3 months)
Trial: 10767520
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate plus L-thyroxine
Trial: 6437815
Drug: TTS‐NTG (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTS‐NTG (25 mg per 10 cm2)
Trial: 31656173
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise therapy (ET) 3 times per week for 12 weeks
Trial: 19067606
Drug: 3rd dose
RxNorm normalized name: CEPHALOSPORIN 3RD GENERATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3rd dose of 1.25 microg H5N1 vaccine
Trial: 19067606
Drug: 3rd dose
RxNorm normalized name: CEPHALOSPORIN 3RD GENERATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3rd dose of 2.5 microg H5N1 vaccine
Trial: 19067606
Drug: 3rd dose
RxNorm normalized name: CEPHALOSPORIN 3RD GENERATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3rd dose of 5 microg H5N1 vaccine
Trial: 19067606
Drug: 3rd dose
RxNorm normalized name: CEPHALOSPORIN 3RD GENERATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3rd dose of 10 microg H5N1 vaccine
Trial: 17544875
Drug: Single-dose inactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose inactive trivalent influenza vaccine
Trial: 17544875
Drug: Infliximab and
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab and immunomodulatory therapy
Trial: 15718325
Drug: Psychoeducational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychoeducational intervention (six weekly sessions of 2 hours)
Trial: 3524182
Drug: Streptokinase (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase (1.0 million units) followed by 72 hours of heparin infusion
Trial: 3524182
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by heparin infusion
Trial: 2493413
Drug: 1.5 mg/h
RxNorm normalized name: dextroamphetamine 1.5 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/h NTG infusion
Trial: 2493413
Drug: 1.5 mg/h
RxNorm normalized name: dextroamphetamine 1.5 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/h NTG infusion after 12-hour infusion-free interval
Trial: 25037243
Drug: Intravitreal diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal diclofenac (IVD) - 500 μg/0.1 ml
Trial: 25037243
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) - 1.25 mg
Trial: 23980355
Drug: Routine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine therapy + Xuebijing (XBJ)
Trial: 17987348
Drug: Physicians' responses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physicians' responses to patients' requests for antidepressants
Trial: 15798812
Drug: Anti-retroviral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-retroviral therapy plus N-acetyl-L-cysteine (NAC) supplementation (600 mg/day)
Trial: 15798812
Drug: Anti-retroviral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-retroviral therapy plus placebo
Trial: 11789125
Drug: Cholinesterase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinesterase inhibitors (donepezil, rivastigmine, metrifonate)
Trial: 30789575
Drug: Supplementary strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementary strength training program (twice per week for 8 weeks)
Trial: 22027191
Drug: Immunonutrition (IM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunonutrition (IM) group: 750 ml of IMPACT plus half‐size hospital meals orally from 5 days before to the day before surgery
Trial: 31778599
Drug: Total incidence
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total incidence of allelic disorders of low drug absorption and metabolism
Trial: 26867336
Drug: Intrathecal isobaric
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal isobaric bupivacaine 8.121 mg
Trial: 26867336
Drug: Intrathecal isobaric
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal isobaric bupivacaine 9.012 mg
Trial: 14522153
Drug: Post-treatment life
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment life expectancy and survival in females from more-deprived areas
Trial: 31056681
Drug: Caffeine (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (median 1.6 mg/L for dipyridamole; 7.4 mg/L for regadenoson)
Trial: 28525981
Drug: Gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 300 mg orally 1 hour before anesthesia and Ramosetron 0.3 mg intravenously at the end of surgery (Group GR)
Trial: 28525981
Drug: Gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 300 mg orally 1 hour before anesthesia (Group G)
Trial: 28525981
Drug: Ramosetron 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 0.3 mg intravenously at the end of surgery (Group R)
Trial: 26375824
Drug: Opioid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid therapy (morphine equivalents)
Trial: 20464539
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C and E (VCE) administration before anesthesia with desflurane
Trial: 20464539
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C and E (VCE) administration